Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $274,051.32 in Stock

Key Points

• EVP Ryan Savitz sold 3,044 Dianthus Therapeutics shares at an average $90.03, receiving about $274,051. He retained 29,276 shares after the sale.
• The article also reports other recent sales by Savitz, including 100,713 shares for about $9.12 million and 17,724 shares for about $1.61 million.
• Dianthus shares traded at $92.48 on Thursday. The company beat quarterly EPS and revenue estimates, while analysts’ consensus rating was “Buy” with a $128.77 price target.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Ryan Savitz sold 3,044 shares of the business's stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $90.03, for a total transaction of $274,051.32. Following the completion of the transaction, the executive vice president owned 29,276 shares in the company, valued at approximately $2,635,718.28. This trade represents a 9.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Ryan Savitz also recently made the following trade(s):

• On Thursday, November 12th, Ryan Savitz sold 17,724 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.56, for a total transaction of $1,605,085.44.
• On Monday, November 9th, Ryan Savitz sold 100,713 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.54, for a total transaction of $9,118,555.02.
• On Tuesday, November 10th, Ryan Savitz sold 2,561 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.14, for a total transaction of $230,848.54.

Dianthus Therapeutics Price Performance

Shares of NASDAQ:DNTH traded up $3.18 during trading on Thursday, reaching $92.48. The stock had a trading volume of 921,016 shares, compared to its average volume of 931,449. The stock has a market capitalization of $5.21 billion, a PE ratio of -23.18 and a beta of 1.47. Dianthus Therapeutics, Inc. has a 52 week low of $34.29 and a 52 week high of $117.88. The business's 50-day moving average price is $89.05 and its 200 day moving average price is $86.15.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, topping analysts' consensus estimates of ($0.94) by $0.13. Dianthus Therapeutics had a negative return on equity of 19.68% and a negative net margin of 7,436.50%. The business had revenue of $1.21 million for the quarter, compared to analyst estimates of $0.46 million. Analysts forecast that Dianthus Therapeutics, Inc. will post -3.55 EPS for the current year.

Wall Street Analyst Weigh In

DNTH has been the topic of several research analyst reports. Citigroup began coverage on Dianthus Therapeutics in a report on Friday, September 4th. They set a "buy" rating and a $156.00 target price on the stock. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $134.00 price target on shares of Dianthus Therapeutics in a report on Thursday, November 5th. JPMorgan Chase & Co. assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, September 11th. They set an "overweight" rating and a $135.00 price target on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Dianthus Therapeutics in a report on Thursday, October 15th. Finally, Truist Financial increased their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $128.77.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. EFG International AG bought a new position in Dianthus Therapeutics in the 2nd quarter worth approximately $49,000. GAMMA Investing LLC lifted its holdings in Dianthus Therapeutics by 83.6% during the 3rd quarter. GAMMA Investing LLC now owns 558 shares of the company's stock worth $49,000 after buying an additional 254 shares in the last quarter. Fifth Third Bancorp boosted its position in Dianthus Therapeutics by 23.6% in the 3rd quarter. Fifth Third Bancorp now owns 676 shares of the company's stock valued at $60,000 after buying an additional 129 shares during the last quarter. Global Retirement Partners LLC bought a new position in Dianthus Therapeutics in the 2nd quarter valued at $93,000. Finally, Nisa Investment Advisors LLC boosted its position in Dianthus Therapeutics by 75.0% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,057 shares of the company's stock valued at $93,000 after buying an additional 453 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company's research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.